Maria Joana Catarata

Dr. Maria Joana Catarata

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 June 2020 in Cancers
Verified
Journal Article
Open access
PDF file
MCMaria Joana Catarata
Maria Joana Catarata
Ricardo Jorge RibeiroRicardo Jorge Ribeiro
Ricardo Jorge Ribeiro
Maria  OliveiraMaria Oliveira
Maria Oliveira
CCCarlos Robalo Cordeiro
Carlos Robalo Cordeiro
Rui MedeirosRui Medeiros
Rui Medeiros
The mechanistic involvement of the renin-angiotensin system (RAS) reaches beyond cardiovascular physiopathology. Recent knowledge pinpoints a pleiotropic role for this system, particularly in the lung, and mainly through locally regulated alternative molecules and secondary pathways. Angiotensin peptides play a role in cell proliferation, immunoinflammatory response, hypoxia and angiogenesis, which are critical biological processes in lung cancer. This manuscript reviews the literature supporting a role for the renin-angiotensin system in the lung tumor microenvironment and discusses whether blockade of this pathway in clinical settings may serve as an adjuvant therapy in lung cancer.

7 November 2019 in BMJ Open
Verified
Journal Article
Open access
PDF file
CJCristina Jácome
Cristina Jácome
APAna Pereira
Ana Pereira
Rute AlmeidaRute Almeida
Rute Almeida
MFManuel Ferreira-Magalhaes
Manuel Ferreira-Magalhaes
MCMariana Couto
Mariana Couto
JFJoao A. da Fonseca
Joao A. da Fonseca
Objective: We aimed to compare patient’s and physician’s ratings of inhaled medication adherence and to identify predictors of patient-physician discordance.Design: Baseline data from two prospective multicentre observational studies.Setting: 29 allergy, pulmonology and paediatric secondary care outpatient clinics in Portugal.Participants: 395 patients (≥13 years old) with persistent asthma.Measures: Data on demographics, patient-physician relationship, upper airway control, asthma control, asthma treatment, forced expiratory volume in one second (FEV1) and healthcare use were collected. Patients and physicians independently assessed adherence to inhaled controller medication during the previous week using a 100 mm Visual Analogue Scale (VAS). Discordance was defined as classification in distinct VAS categories (low 0–50; medium 51–80; high 81–100) or as an absolute difference in VAS scores ≥10 mm. Correlation between patients’ and physicians’ VAS scores/categories was explored. A multinomial logistic regression identified the predictors of physician overestimation and underestimation.Results: High inhaler adherence was reported both by patients (median (percentile 25 to percentile 75) 85 (65–95) mm; 53% VAS>80) and by physicians (84 (68–95) mm; 53% VAS>80). Correlation between patient and physician VAS scores was moderate (rs=0.580; p<0.001). Discordance occurred in 56% of cases: in 28% physicians overestimated adherence and in 27% underestimated. Low adherence as assessed by the physician (OR=27.35 (9.85 to 75.95)), FEV1≥80% (OR=2.59 (1.08 to 6.20)) and a first appointment (OR=5.63 (1.24 to 25.56)) were predictors of underestimation. An uncontrolled asthma (OR=2.33 (1.25 to 4.34)), uncontrolled upper airway disease (OR=2.86 (1.35 to 6.04)) and prescription of short-acting beta-agonists alone (OR=3.05 (1.15 to 8.08)) were associated with overestimation. Medium adherence as assessed by the physician was significantly associated with higher risk of discordance, both for overestimation and underestimation of adherence (OR=14.50 (6.04 to 34.81); OR=2.21 (1.07 to 4.58)), while having a written action plan decreased the likelihood of discordance (OR=0.25 (0.12 to 0.52); OR=0.41 (0.22 to 0.78)) (R2=44%).Conclusion: Although both patients and physicians report high inhaler adherence, discordance occurred in half of cases. Implementation of objective adherence measures and effective communication are needed to improve patient-physician agreement.

23 April 2020 in Journal of Investigational Allergology and Clinical Immunology
Verified
Journal Article
Closed access
IGINSPIRERS group
INSPIRERS group
CJCristina Jácome
Cristina Jácome
Rute AlmeidaRute Almeida
Rute Almeida
APAm Pereira
Am Pereira
LAL Araújo
L Araújo
JFJ Almeida Fonseca
J Almeida Fonseca

1 October 2025 in Breathe
Verified
Journal Article
Open access
CCCarla Carvalho
Carla Carvalho
SHSaskia van Heumen
Saskia van Heumen
FFFaustina Funke
Faustina Funke
MHMarjolein A. Heuvelmans
Marjolein A. Heuvelmans
MSMariana Serino
Mariana Serino
MCMaria Joana Catarata
Maria Joana Catarata
The implementation of lung cancer screening with low-dose computed tomography has significantly increased the detection of pulmonary nodules, most of which are peripherally located and difficult to access. Effectively addressing these findings remains a clinical challenge, particularly in balancing diagnostic accuracy with procedural risk. Advances in interventional pulmonology have enabled minimally invasive approaches that may support both diagnosis and treatment, especially in selected patients with peripherally located nodules or limited surgical options. However, evidence on their effectiveness, accessibility and integration into screening workflows remains variable. In this review, we discuss the current role of interventional pulmonology in the context of lung cancer screening, outlining its potential benefits, limitations, and areas requiring further research to define its place within multidisciplinary care.

26 May 2020 in American Journal of Hospice and Palliative Medicine®
Verified
Journal Article
Closed access
PDF file
MCMaria Joana Catarata
Maria Joana Catarata
SSSandra Saleiro
Sandra Saleiro
VAVânia Sá Araújo
Vânia Sá Araújo
A significant proportion of patients with advanced primary or metastatic intrathoracic malignancy will eventually develop central airway obstruction. The morbidity associated with malignant airway obstruction (MAO) is considerable and the management is difficult. Our aim was to evaluate the outcomes of tracheobronchial stenting in patients with MAO and its role in palliative care. This retrospective study involved a consecutive case series of patients with advanced cancer with MAO who underwent tracheobronchial stenting between August 2014 and August 2019. The European Cooperative Oncology Group (ECOG) scale was used to evaluate patient functional status before and after tracheobronchial stenting. Univariate survival analysis included Kaplan-Meier curves with Log-Rank test, while Cox regression was used as a multivariate analysis. We included 28 patients with median age of 55.0 years (interquartile range = 49.3-66.5) and 89.3% male. The most frequent primary tumour was the esophagus followed by lungs. The majority of the patients (75%) expressed immediate symptom relief after stenting and there was a significant improvement in the mean ECOG performance status (PS; P = .005). There was no intraprocedure mortality and complications were observed in 6 patients. The median survival after airway stenting was 39.0 days (95% CI = 32.2-45.8) with poorer PS after stent insertion associated with lower overall survival (hazard ratio = 2.3 [95% CI = 1.1-4.9], P = .030) on multivariate analysis. Airway stent is a safe and effective procedure that offers rapid palliation of symptoms with no major complications. Therefore, stent placement should be considered as part of the treatment of patients with terminal cancer.

10 March 2021 in Pulmonology
Verified
Journal Article
Open access
MCMaria Joana Catarata
Maria Joana Catarata
MLMargarida Lourenço
Margarida Lourenço
MMMaria Fátima Martins
Maria Fátima Martins
JFJoão Frade
João Frade
APAlice Pêgo
Alice Pêgo
Ricardo Jorge RibeiroRicardo Jorge Ribeiro
Ricardo Jorge Ribeiro
AGXT gene codes for the enzyme alanine glyoxylate aminotransferase, which is involved in hepatic peroxisomal metabolism of platinum-based chemotherapeutic agents. The association of genetic variant AGXT rs34116584 on the clinical outcome and response to chemotherapy of patients with non-small cell lung cancer (NSCLC) remains to be established. Our aim was to evaluate the association of functional AGXT gene polymorphism in NSCLC progression, considering as primary and secondary endpoint, progression free survival (PFS) and overall survival (OS), respectively. Genotyping of theAGXT rs34116584 genetic polymorphism was performed by mass spectrometry on 168 DNA samples from patients with NSCLC (stages IIIA-IVB). Univariate survival analysis included the study of Kaplan-Meier curves with the Log-Rank test, while Cox regression was used as a multivariate analysis. Multivariate analysis showed shorter PFS for T carriers [HR=2.0, 95% CI, 1.4-3.0, p<0.0001] and shorter OS [HR=1.8, 95% CI, 1.1-3.0, p=0.017] globally, as well as in a subgroup of patients (n=144) treated with first line platinum-based chemotherapy [HR=2.0, 95% CI, 1.3-3.1, p=0.001] and [HR=1.8, 95% CI, 1.1-3.1, p=0.026], respectively. This polymorphism seems to have an impact on NSCLC progression, opening new perspectives for its inclusion as a pharmacogenetic predictor of response to platinum-based chemotherapy.